Skip to main content

Table 1 Clinical characteristics and Demographics of HIV-HCV coinfected patient population at Yale-New Haven Hospital HIV Clinic

From: Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients

Characteristic Total patients
N = 219 (% or range)
Characteristic Total patients
N = 219 (% or range)
Age in years, median (range) 56 (28–74) HIV viral load < 20 copies/mL, no. (%) 174 (80)
Race / ethnicity, no. (%)   CD4 count, median (range) 513 (27–2060)
 Black 117 (53) On ART, no. (%) 205 (94)
 White 68 (31) NRTI backbone  
 Hispanic 30 (14) Tenofovir (TDF or TAF)/ emtricitabine 135 (62)
 Other 4 (2) Abacavir/ lamivudine 47 (22)
Gender, no. (%)   NNRTI  
 Male 147 (67) Efavirenz 36 (16)
 Female 72 (33) Rilpivirine 22 (10)
HCV Genotype, no. (%)   Etravirine 10 (4.6)
 1a 107 (49) Protease inhibitors/ ritonavir  
 1b 27 (12) Atazanavir 30 (14)
 2 5 (2) Darunavir 31 (14)
 3 6 (3) Lopinavir 4 (2)
 4 5 (2) Integrase inhibitors  
 Unknown 69 (32) Dolutegravir 51 (23)
HCV viral load, mean IU/mL (range) 5.83 M (15–69,000,000) Raltegravir 46 (21)
Cirrhosis status, no. (%)   Elvitegravir 10 (5)
 Non-cirrhotic 79 (36) Comorbidities, no (%)  
 Compensated 111 (51) EtOH use 184 (84)
 Decompensated 29 (13) Current 51 (23)
HCV prior treatment, no. (%)   Prior 133 (61)
 Yes 54 (25) IVDU 192 (88)
 No 156 (71) Current 32 (15)
 Unknown 9 (4) Prior 160 (73)
HBV Sag positive, no. (%) 0 (0) Psychiatric disorder 114 (52)
   *Abnormal Creatinine Clearance 40 (18)
  1. ART antiretroviral therapy, HBV, EtOH ethanol (alcohol), Hepatitis B virus; HCV Hepatitis C virus, HIV Human immunodeficiency virus, IVDU intravenous drug use, NNRTI non-nucleoside(tide) reverse transcriptase inhibitor, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate
  2. *Abnormal creatinine clearance < 60ml/min